Welcome to our dedicated page for Heron Therapeutics news (Ticker: HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics stock.
Heron Therapeutics, Inc. reports commercial and financial developments for a commercial-stage biotechnology business focused on acute care and oncology products. News commonly covers revenue performance and guidance for the Acute Care franchise, including ZYNRELEF and APONVIE, as well as oncology product updates involving CINVANTI and the broader product portfolio.
Company updates also address APONVIE’s role as an FDA-approved IV NK-1 receptor antagonist for prevention of postoperative nausea and vomiting in adults, ZYNRELEF product-handling initiatives for hospital and ambulatory surgical center use, distribution and sales-force activity, intellectual-property matters, and board or governance changes.
Heron Therapeutics (Nasdaq:HRTX) reported Q2 2026 net product sales of $37.7 million, up 9% sequentially and 1.3% year-over-year, with Acute Care revenue up 43.9% year-over-year and Oncology down 15.9%. ZYNRELEF generated $11.1 million and APONVIE $4.3 million in Q2, with year-over-year growth of 35.0% and 73.6%, respectively. CINVANTI revenue declined 9.7% and SUSTOL declined 77.5% year-over-year.
The company posted a Q2 2026 net loss of $5.5 million versus a $2.4 million loss a year earlier, and a six‑month 2026 net loss of $13.6 million versus a $0.3 million profit in 2025. Heron ended Q2 with $42.7 million in cash, cash equivalents and short‑term investments and total assets of $252.3 million.
Heron amended its credit facility with Hercules Capital, resetting financial covenants through 2027 and providing for a total potential reduction of $17.5 million in outstanding principal. The company withdrew full‑year 2026 guidance for net product sales and Adjusted EBITDA and is considering strategic alternatives following a June 2026 patent decision affecting CINVANTI.
Heron Therapeutics (Nasdaq: HRTX) will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report its second quarter 2026 financial results and discuss recent business highlights. Investors can access the call via a registration-based dial-in and through a webcast in the Investor Relations section of www.herontx.com. An archived replay of both the teleconference and webcast will be available on the company’s website for 60 days following the event.
Heron Therapeutics (Nasdaq:HRTX) announced that the U.S. District Court for the District of Delaware ruled on patent litigation with Azurity regarding CINVANTI (aprepitant) injectable emulsion, holding asserted claims of U.S. Patent Nos. 12,115,255 and 12,290,520 invalid.
According to Heron, the decision does not affect prior settlement agreements related to CINVANTI or APONVIE. The company intends to appeal to the U.S. Court of Appeals for the Federal Circuit and states it will continue defending its intellectual property rights.
Heron Therapeutics (Nasdaq:HRTX) reported Q1 2026 total net revenue of $34.7 million, down 10.8% year-over-year. Acute Care net revenue grew 32% to $13.6 million, while Oncology Supportive Care fell 26.3% to $21.1 million.
Heron reaffirmed 2026 guidance of $173–$183 million net revenue and $10–$20 million Adjusted EBITDA, ended Q1 with $44.8 million in cash and investments, and reached a settlement with Baxter in CINVANTI patent litigation, with the related case dismissed on April 28, 2026.
Heron Therapeutics (Nasdaq: HRTX) will report first quarter 2026 financial results on Monday, May 11, 2026 at 8:30 a.m. ET via a conference call and live webcast.
The call requires registration for dial-in details; participants are encouraged to dial in 15 minutes early. A webcast and a 60-day archive will be available on Heron's Investor Relations website at www.herontx.com.
Heron Therapeutics (NASDAQ: HRTX) reported $154.9 million net revenue for 2025, driven by a 65.1% year‑over‑year rise in its Acute Care franchise. The company issued 2026 guidance of $173–$183 million net revenue and $10–$20 million adjusted EBITDA.
Key 2025 items: APONVIE and ZYNRELEF growth, CMS product‑specific J‑Codes for both products, completion of the ZYNRELEF vial access needle transition, Oncology revenue of >$105 million, and cash of $46.6 million at year end.
Heron Therapeutics (Nasdaq: HRTX) will report fourth quarter and full year 2025 results on Thursday, February 26, 2026 with a conference call and live webcast at 8:30 a.m. ET.
According to the company, the call will review financial results and recent business highlights; a replay will be available on Heron’s investor website for 60 days.
Heron Therapeutics (Nasdaq: HRTX) reported preliminary, unaudited net revenue of approximately $40.5 million for Q4 2025 and $154.9 million for full-year 2025. Key Q4 contributors were ZYNRELEF (~$12.5M), CINVANTI (~$22.9M), APONVIE (~$3.8M) and SUSTOL (~$1.3M).
ZYNRELEF delivered the largest quarter-over-quarter increase in the portfolio in Q4, rising ~35% vs Q3 2025. Management highlighted momentum in the Acute Care franchise across ZYNRELEF and APONVIE and described continued progress across the business during 2025.
Heron Therapeutics (Nasdaq: HRTX) announced that APONVIE (aprepitant) injectable emulsion is included in the newly released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) published Dec 4, 2025. The Guidelines identify APONVIE as an NK-1 receptor antagonist option for adult PONV prevention, note its 30-second IV administration and long half-life, and cite evidence that aprepitant alone or in combinations significantly reduces PONV and postoperative vomiting compared with alternatives such as ondansetron. The Guidelines emphasize multimodal prophylaxis for high-risk patients (three or more risk factors) and recommend long-acting antiemetics before discharge to reduce post-discharge nausea and vomiting (PDNV).
Heron Therapeutics (Nasdaq: HRTX) reported Q3 2025 net revenue of $38.2 million and year-to-date net revenue of $114.3 million, and reaffirmed full-year 2025 net revenue guidance of $153.0–$163.0 million with adjusted EBITDA guidance of $9.0–$13.0 million. Acute Care revenue grew 67.2% in Q3 2025; ZYNRELEF net revenue rose 49% in Q3 2025 and APONVIE net revenue rose 173% in Q3 2025 versus prior year.
Commercial actions include a completed roll-out of the Vial Access Needle (VAN) for ZYNRELEF, a permanent product-specific J-code effective October 1, 2025, a reorganized ZYNRELEF sales team, and stability testing for a ZYNRELEF prefilled syringe with potential approval in 2027. Cash, cash equivalents and short-term investments were $55.5 million as of September 30, 2025.